Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
A major clinical trial with 3,500 participants showed that semaglutide reduces disease progression by 24% and lowers the risk of kidney failure and cardiovascular death by 5%
Therefore, studies assessing the quality of prescribing and characteristics of patients receiving GLP-1 RA are urgently needed
Switching from Tirzepatide
Fast Australia-wide delivery
In 2023, Pfizer terminated the clinical development of two oral GLP-1 small molecule agonists, Lotiglipron and Danuglipron
Customer Service Hours
.png)
US$ 20.47
US$ 25.33
US$ 22.69
US$ 28.88
